FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2633-2635 June 12, 2008 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The Action to Control Cardiovascular Risk in Diabetes Study Group Related Article by The ADVANCE Collaborative Group PubMed Citation

Cardiovascular disease in patients with diabetes is clearly associated with the degree of hyperglycemia, as measured clinically with the use of glycated hemoglobin.^1,2,3 However, there remains an unanswered question in diabetes management: Does the targeting of near normal levels of glycated hemoglobin reduce the rate of cardiovascular events? Randomized clinical trials that address this question are ongoing.

In this issue of the Journal, results are presented from two recently completed multicenter clinical trials, the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial (ClinicalTrials.gov number, NCT00000620 [ClinicalTrials.gov] )⁴ and the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified . . . [Full Text of this Article]

Source Information

From the Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge.

This article (10.1056/NEJMe0803831) was published at www.nejm.org on June 6, 2008.

This article has been cited by other articles:

• Bianchi, C., Miccoli, R., Daniele, G., Penno, G., Del Prato, S. (2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. Diabetes Care 32: S342-S348 [Full Text]  
• Bailey, C. J., Blonde, L., Del Prato, S., Leiter, L. A., Nesto, R., Global Partnership for Effective Diabetes Manageme, (2009). What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diabetes and Vascular Disease Research 6: 283-287 [Abstract]  
• Potenza, M. A., Gagliardi, S., De Benedictis, L., Zigrino, A., Tiravanti, E., Colantuono, G., Federici, A., Lorusso, L., Benagiano, V., Quon, M. J., Montagnani, M. (2009). Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am. J. Physiol. Endocrinol. Metab. 297: E685-E694 [Abstract] [Full Text]  
• Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., Izquierdo, R. E., Ebner, S., Silver, S., Petkova, E., Kong, J., Eimicke, J. P., IDEATel Consortium, (2009). A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. J. Am. Med. Inform. Assoc. 16: 446-456 [Abstract] [Full Text]  
• Kassabian, S. G. (2009). Hemoglobin A1c Testing, Board-Recertification Scores, and Treatment Outcomes. Arch Intern Med 169: 417-417 [Full Text]